AMED Quote, Financials, Valuation and Earnings

Chemed has a net margin of 2.88% compared to Amedisys's net margin of 12.5%. Amedisys's return on equity of 7.23% beat Chemed's return on equity of 26.22%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.1%. On the other hand Chemed has an analysts' consensus of $663.67 which suggests that it could grow by 24.75%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

Amedisys has a beta of 0.719, which suggesting that the stock is 28.1% less volatile than S&P 500. In comparison Chemed has a beta of 0.474, suggesting its less volatile than the S&P 500 by 52.593%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chemed offers a yield of 0.34% to investors and pays a quarterly dividend of $0.50 per share. Amedisys pays -- of its earnings as a dividend. Chemed pays out 8.62% of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amedisys quarterly revenues are $587.7M, which are smaller than Chemed quarterly revenues of $606.2M. Amedisys's net income of $16.9M is lower than Chemed's net income of $75.8M. Notably, Amedisys's price-to-earnings ratio is 36.57x while Chemed's PE ratio is 26.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 3.41x for Chemed. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 2.88% compared to Amedisys's net margin of 4.21%. Amedisys's return on equity of 7.23% beat Option Care Health's return on equity of 14.65%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.1%. On the other hand Option Care Health has an analysts' consensus of $30.11 which suggests that it could grow by 24.74%. Given that Option Care Health has higher upside potential than Amedisys, analysts believe Option Care Health is more attractive than Amedisys.

Amedisys has a beta of 0.719, which suggesting that the stock is 28.1% less volatile than S&P 500. In comparison Option Care Health has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.359%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $587.7M, which are smaller than Option Care Health quarterly revenues of $1.3B. Amedisys's net income of $16.9M is lower than Option Care Health's net income of $53.9M. Notably, Amedisys's price-to-earnings ratio is 36.57x while Option Care Health's PE ratio is 20.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 0.88x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 2.88% compared to Amedisys's net margin of -42.82%. Amedisys's return on equity of 7.23% beat OptimizeRx's return on equity of -20.12%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.1%. On the other hand OptimizeRx has an analysts' consensus of $9.64 which suggests that it could grow by 78.24%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

Amedisys has a beta of 0.719, which suggesting that the stock is 28.1% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.363, suggesting its more volatile than the S&P 500 by 36.342%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $587.7M, which are larger than OptimizeRx quarterly revenues of $21.3M. Amedisys's net income of $16.9M is higher than OptimizeRx's net income of -$9.1M. Notably, Amedisys's price-to-earnings ratio is 36.57x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 1.11x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.

Regional Health Properties has a net margin of 2.88% compared to Amedisys's net margin of -23.24%. Amedisys's return on equity of 7.23% beat Regional Health Properties's return on equity of -489.72%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.1%. On the other hand Regional Health Properties has an analysts' consensus of -- which suggests that it could grow by 175.42%. Given that Regional Health Properties has higher upside potential than Amedisys, analysts believe Regional Health Properties is more attractive than Amedisys.

Amedisys has a beta of 0.719, which suggesting that the stock is 28.1% less volatile than S&P 500. In comparison Regional Health Properties has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.677%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regional Health Properties offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Regional Health Properties pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $587.7M, which are larger than Regional Health Properties quarterly revenues of $4.2M. Amedisys's net income of $16.9M is higher than Regional Health Properties's net income of -$982K. Notably, Amedisys's price-to-earnings ratio is 36.57x while Regional Health Properties's PE ratio is 0.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.31x versus 0.26x for Regional Health Properties. Usually stocks with elevated PS ratios are considered overvalued.